Ocera Therapeutics Concludes Patient Enrollment In Phase 2B ASTUTE Trial
AST-120 adsorbs ammonia and other gut derived toxins that factor prominently in the underlying cause of mild hepatic encephalopathy (MHE). The study is a randomised, double blind, multicenter
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.